Behavioural screen in C. elegans reveals Parkinson’s drug candidates 24 February 2021 | By Victoria Rees (Drug Target Review) Researchers have developed a workflow to study the behaviour of C. elegans in a high-throughput screen to identify Parkinson's disease drugs.
Over 87,000 papers published on coronavirus since start of pandemic 24 February 2021 | By Victoria Rees (Drug Target Review) Between January and October 2020, scientists globally have published more than 87,000 papers about the coronavirus.
Neuron damage from ALS reversed with new compound 24 February 2021 | By Victoria Rees (Drug Target Review) Scientists have developed a compound that stops the degeneration of upper motor neurons, a contributor to amyotrophic lateral sclerosis (ALS).
New CRISPR tool could enable gene editing over time, study shows 24 February 2021 | By Victoria Rees (Drug Target Review) Researchers have shown that a guide RNA can be used in CRISPR gene editing to ensure sequential Cas9 cuts to DNA.
Screening of approved drugs reveals potential treatment for COVID-19 23 February 2021 | By Victoria Rees (Drug Target Review) Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.
Researchers identify new therapeutic targets on SARS-CoV-2 Spike protein 23 February 2021 | By Victoria Rees (Drug Target Review) Researchers have found that the S1/S2 cleavage of the SARS-CoV-2 Spike protein could be a potential target for COVID-19 therapeutics.
Experimental mAb subdues type 1 diabetes in laboratory mice 23 February 2021 | By Victoria Rees (Drug Target Review) A monoclonal antibody given to mice reversed type 1 diabetes by suppressing the actions of glucagon, a study has shown.
High-throughput screening assay for macrocyclic peptides developed 23 February 2021 | By Victoria Rees (Drug Target Review) A high-throughput screening assay for macrocyclic peptides with affinity to ubiquitin has been created by researchers.
New technology enables predictive design of engineered human cells 22 February 2021 | By Victoria Rees (Drug Target Review) Researchers have developed a computer modelling programme that can produce genetic circuits for cellular engineering.
Analysis conducted on glycan structure from sheep prion strains 22 February 2021 | By Victoria Rees (Drug Target Review) Using liquid chromatography/mass spectrometry, researchers have revealed no major differences in glycan structures in two prion strains.
Researchers find MAPK4 enzyme presents target for prostate cancer 22 February 2021 | By Victoria Rees (Drug Target Review) Research has shown that MAPK4 activates two molecules in cellular signalling pathways involved in prostate cancer growth.
Study shows that FOXO3 gene protects brain stem cells 22 February 2021 | By Victoria Rees (Drug Target Review) A version of the FOXO3 gene can protect brain stem cells from stress during ageing, according to a new study.
UK Government to fund four studies investigating long COVID 19 February 2021 | By Victoria Rees (Drug Target Review) The UK Government will give £18.5 million in funding to four studies researching the causes and potential treatments of long COVID.
Team modifies therapeutic molecule to improve stroke treatment 19 February 2021 | By Victoria Rees (Drug Target Review) Researchers have shown that adding a polymer to glutamate-oxaloacetate transaminase means the molecule can treat stroke for up to six days in rats.
Bile duct organoids could be used as cell therapy for regenerative medicine 19 February 2021 | By Victoria Rees (Drug Target Review) For the first time, scientists have grown bile duct organoids that could repair damaged ducts and livers as a new cell therapy.
